[go: up one dir, main page]

SG11202011242SA - SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS - Google Patents

SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Info

Publication number
SG11202011242SA
SG11202011242SA SG11202011242SA SG11202011242SA SG11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA SG 11202011242S A SG11202011242S A SG 11202011242SA
Authority
SG
Singapore
Prior art keywords
rur20kd
related compositions
selective treg
treg stimulator
stimulator
Prior art date
Application number
SG11202011242SA
Other languages
English (en)
Inventor
Peter Benedict Kirk
John L Langowski
Jonathan Zalevsky
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67002369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202011242S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of SG11202011242SA publication Critical patent/SG11202011242SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202011242SA 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS SG11202011242SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862674244P 2018-05-21 2018-05-21
PCT/US2019/033100 WO2019226538A1 (en) 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Publications (1)

Publication Number Publication Date
SG11202011242SA true SG11202011242SA (en) 2020-12-30

Family

ID=67002369

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011242SA SG11202011242SA (en) 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Country Status (21)

Country Link
US (1) US20210205413A1 (pt)
EP (1) EP3796940A1 (pt)
JP (3) JP7235772B2 (pt)
KR (2) KR102706554B1 (pt)
CN (2) CN112399859B (pt)
AU (3) AU2019274409B2 (pt)
BR (1) BR112020021564A2 (pt)
CA (1) CA3100204A1 (pt)
CL (1) CL2020003008A1 (pt)
CO (1) CO2020014510A2 (pt)
CR (1) CR20200546A (pt)
DO (1) DOP2020000212A (pt)
EA (1) EA202092489A1 (pt)
EC (1) ECSP20074392A (pt)
IL (2) IL312646A (pt)
JO (1) JOP20200290A1 (pt)
MX (1) MX2024012807A (pt)
PE (1) PE20211307A1 (pt)
PH (1) PH12020551976A1 (pt)
SG (1) SG11202011242SA (pt)
WO (1) WO2019226538A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
US20230102464A1 (en) * 2020-01-15 2023-03-30 Jenkem Technology Co., Ltd. (Tianjin) Method for preparing pegylated biomolecule with controllable binding sites
JP2021143142A (ja) * 2020-03-11 2021-09-24 花王株式会社 制御性t細胞誘導剤
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗peg抗體的化合物
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
MX2024007345A (es) 2021-12-14 2024-09-30 Nektar Therapeutics Pautas posologicas para el estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas.
CN116212040B (zh) * 2023-02-14 2025-11-28 河北菲尼斯生物技术有限公司 一种作为Treg靶向调节剂的PEG修饰IL-2的组合物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
HUE043911T2 (hu) 2003-05-23 2019-09-30 Nektar Therapeutics Két PEG láncot tartalmazó PEG származékok
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
KR20200070407A (ko) * 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Il-2 부분 및 중합체의 접합체
MX384095B (es) 2011-03-11 2025-03-14 Hopitaux Paris Assist Publique Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
WO2017156720A1 (zh) 2016-03-16 2017-09-21 谢彦晖 糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病

Also Published As

Publication number Publication date
EP3796940A1 (en) 2021-03-31
KR102706554B1 (ko) 2024-09-12
AU2019274409B2 (en) 2022-07-14
AU2025200920A1 (en) 2025-03-13
MX2024012807A (es) 2024-11-08
CA3100204A1 (en) 2019-11-28
AU2022246440B2 (en) 2024-11-14
KR20240137713A (ko) 2024-09-20
JP2024116272A (ja) 2024-08-27
PE20211307A1 (es) 2021-07-20
CN112399859B (zh) 2024-11-29
CN120131983A (zh) 2025-06-13
JP2023052053A (ja) 2023-04-11
PH12020551976A1 (en) 2021-09-13
WO2019226538A1 (en) 2019-11-28
CL2020003008A1 (es) 2021-07-30
CO2020014510A2 (es) 2021-03-08
AU2022246440A1 (en) 2022-11-03
EA202092489A1 (ru) 2021-03-16
IL278528A (pt) 2021-01-31
JP7235772B2 (ja) 2023-03-08
ECSP20074392A (es) 2021-03-31
CR20200546A (es) 2021-05-18
JP2021523922A (ja) 2021-09-09
DOP2020000212A (es) 2021-03-15
BR112020021564A2 (pt) 2021-03-02
US20210205413A1 (en) 2021-07-08
KR20210002577A (ko) 2021-01-08
JP7801991B2 (ja) 2026-01-19
IL278528B2 (en) 2024-10-01
AU2019274409A1 (en) 2020-11-12
JOP20200290A1 (ar) 2020-11-15
IL312646A (en) 2024-07-01
IL278528B1 (en) 2024-06-01
CN112399859A (zh) 2021-02-23

Similar Documents

Publication Publication Date Title
IL280134A (en) Anti-CD112R preparations and methods
SG11202011242SA (en) SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
IL277079A (en) Cartirin preparations and methods of use
SG11202105626TA (en) Oligonucleotide compositions and methods thereof
ZA202004678B (en) Compositions comprising co-selected microbiota and methods for use thereof
GB201807325D0 (en) Compositions and methods
GB202201859D0 (en) Novel methods and compositions
SG11202104448WA (en) Compositions and methods
ZA202101362B (en) Compositions and methods for treating the eye
GB201913204D0 (en) Compositions and methods and uses relating thereto
IL271256A (en) Preparations and methods for the treatment of teopathy
ZA202101342B (en) Compositions and methods for treating the eye
IL279059A (en) Methods and preparations for killing spores
ZA202004533B (en) Skin-brightening compositions and methods
GB201810852D0 (en) Compositions, uses and methods
GB201817444D0 (en) Methods and compositions
GB201815402D0 (en) Compositions and methods and uses relating thereto
IL290325A (en) Biopharmaceutical preparations and related methods
GB201804163D0 (en) Uses, compositions and methods
GB201819987D0 (en) Methods and compositions
ZA202103276B (en) Bioflavonoid compositions and their use
ZA202101360B (en) Compositions and methods for treating the eye
ZA202101361B (en) Compositions and methods for treating the eye
GB201804092D0 (en) Methods and compositions
SG11202108262VA (en) Bacterialcidal methods and compositions